|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-7-10
|
|
pubmed:abstractText |
Irinotecan (CPT-11) and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles. Phase I studies have shown that single-agent full doses of both drugs can be safely combined. The aim of this multicenter study was to assess the efficacy and toxicity of the combination in patients with 5-fluorouracil (5-FU)-refractory ACC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1121-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12853356-Adult,
pubmed-meshheading:12853356-Aged,
pubmed-meshheading:12853356-Antimetabolites, Antineoplastic,
pubmed-meshheading:12853356-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12853356-Camptothecin,
pubmed-meshheading:12853356-Colorectal Neoplasms,
pubmed-meshheading:12853356-Disease Progression,
pubmed-meshheading:12853356-Drug Administration Schedule,
pubmed-meshheading:12853356-Drug Resistance, Neoplasm,
pubmed-meshheading:12853356-Female,
pubmed-meshheading:12853356-Fluorouracil,
pubmed-meshheading:12853356-Humans,
pubmed-meshheading:12853356-Infusions, Intravenous,
pubmed-meshheading:12853356-Male,
pubmed-meshheading:12853356-Middle Aged,
pubmed-meshheading:12853356-Quinazolines,
pubmed-meshheading:12853356-Survival Analysis,
pubmed-meshheading:12853356-Thiophenes,
pubmed-meshheading:12853356-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
|
|
pubmed:affiliation |
Medical Oncology, Hospital Universitario La Fe, Valencia, Spain. aparicio_josurt@gva.es.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
